-+ 0.00%
-+ 0.00%
-+ 0.00%

INNOVENT'S PARTNER OLLIN BIOSCIENCES ANNOUNCES FINAL DATA FROM RANDOMIZED HEAD-TO-HEAD STUDY OF IBI324 COMPARED TO FARICIMAB (VABYSMO) IN WET AGE-RELATED MACULAR DEGENERATION AND DIABETIC MACULAR EDEMA

Reuters·03/31/2026 00:00:00

Please log in to view news